4-aminoquinazoline analogs: A novel class of anticancer agents

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 8, 2013, Pages 1177-1194

  Singh, Kalpana ^a   Sharma, P P ^b   Kumar, A ^c   Chaudhary, Anurag ^c   Roy, R K ^a  

^a Dr KNModi Institute of Pharmaceutical Education & Research Modinagar   (India)

^b GURUKUL KANGRI UNIVERSITY   (India)

^c SWAMI VIVEKANAND SUBHARTI UNIVERSITY   (India)

Author keywords

4 aminoquinazoline; Antitumor; Apoptosis; Cytotoxic; Epidermal growth factor receptor; Tyrosine kinase

Indexed keywords

(S) 4 AMINOQUINAZOLINE; 2 (1,40 BIPIPERIDINE 10 YL) N CYCLOHEPTYL 6,7 DIMETHOXYQUINAZOLIN 4 AMINE; 2 (2 THIENO) 4 [4 SULFONAMIDOBENZYLAMINO] 6 IODO QUINAZOLINE; 2 AMINOQUINAZOLINE; 4 (PHENYLAMINO) PYRIDO [3,2 D] PYRIMIDINE 6 ACRYLAMIDE; 4 (PHENYLAMINO) QUINAZOLINE; 4 (THIOPHENOXY) QUINAZOLINE; 4 [[3 CHLORO 4 FLUOROPHENYL] AMINO] 6,7 DIMETHOXY QUINAZOLINE; 4 AMINOQUINAZOLINE; 4 ANILINOPYRIDO [3,4] PYRIMIDINE; 4 ANILINOQUINAZOLINE; 4 ARYLAMINOQUINAZOLINE; 6 ACRYLAMIDO 4 (2 FLUOROANILINO) QUINAZOLINE; 6 AMINOPYRIDO [3,4 D] PYRIMIDINE; 6 AMINOQUINAZOLINE; 6,7 DIALKOXY 4 ANILINOQUINAZOLINE; 6,7,8 TRIMETHOXY 4 CHLOROQUINAZOLINE; 7,8 BIS (METHOXYMETHYL) 7,8 DIHYDRO [1,4] DIOXINO [2,3] QUINAZOLINE; CHEMOKINE RECEPTOR CCR ANTAGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LAPATINIB; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; PROTEIN TYROSINE KINASE; PYRIDO[3,4 D]PYRIMIDINE; QUINAZOLINE DERIVATIVE; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CYTOTOXICITY; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; OVARY CARCINOMA; PANCREAS CARCINOMA; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84881492201     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313080006     Document Type: Article

References (55)

1. Adel, S. El-Azab; Mohamed, A. Al-Omar; Alaa A.M; Naglaa, I. Abdel-Aziz; Magda, A.-A. El-Sayed; Abdulaziz, M. Aleisa; Mohamed, M. Sayed-Ahmed; Sami, G. Abdel-Hamide. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study. E. J. Med. Chem., 2010, 45, 4188-4198.
2. Chandregowda, V.; Kush A.K.; Reddy G.C. Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives. E. J. Med. Chem., 2009, 44, 3046-3055.
3. Cakici, M.; Catir, M.; Karabuga, S.; Kilic, H.; Ulukanli, S.; Gulluce, M.; Orhan, F. Synthesis and biological evaluation of (S)- 4-aminoquinazoline alcohols. Tetrahedron: Asym., 2010, 21, 2027-2031.
4. Yokoyama, K.; Noriko, I.; Susumu, I.; Noriyuki, K.; Naoyuki, M,; Wataru, H.; Shingo, Y.; Yohei, K.; Kazuyuki, H.; Takahiro, M.; Shin-ichi, O.; Yuzo, M.; Makoto, T.; Mitsuaki, O. Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines. Bioorg. Med. Chem., 2009, 17, 64-73.
5. Yokoyama, K.; Noriko, I.; Susumu, I.; Noriyuki, K.; Naoyuki, M,; Wataru, H.; Shingo, Y.; Yohei, K.; Kazuyuki, H.; Takahiro, M.; Shin-ichi, O.; Yuzo, M.; Makoto, T.; Mitsuaki, O. Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines. Bioorg. Med. Chem., 2008, 16, 7021-7032.
6. Gang, L.; Hu, D.Y.; Jin, L.H.; Song, B.A.; Song, Y.; Liu, P.S.; Bhadury, P.S.; Yao, M.; Luo, H.; Zhou, X. Synthesis and bioactivities of 6,7,8-trimethoxy-N aryl-4-aminoquinazoline derivative. Bioorg. Med. Chem., 2007, 15, 6608-6617.
7. Lee, J.Y.; Park, Y.K.; Seo, S.H.; Yang, B.S.; Park, H.; Lee, Y.S. 7- Substituted-[1,4]dioxano[2,3-g]quinazolines as Inhibitors of Epidermal Growth Factor Receptor Kinase. Arch. Pharm. Pharm. Med. Chem., 2002, 10, 487-494.
8. Montgomery, R.B. Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant egf receptor function. J. Cancer, 2002, 101, 111-117.
9. Shukla, G.; Tiwari, A.K. Singh, V.K. Bajpai, A. Chandra, H.; Mishra, A.K. Effect of a Novel Series of Benzothiazolo- Quinazolones on Epidermal Growth Factor Receptor (EGFR) and Biological Evaluations. Chem. Biol. Drug Des., 2008, 72, 533-539.
10. Lee, J.Y.; Park, Y.K.; Seo, S.H.; Yang, B.S.; Park, H.; Lee, Y.S. Synthesis and Biological Evaluation of Bis(methoxymehl)-7,8- dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR Tyrosine Kinase Inhibitors. Arch. Pharm. Chem. Life Sci., 2005, 338, 502-505.
11. Antipenko, L.N.; Karpenko, A.V.; Kovalenko, S.I.; Katsev, A.M.; Komarovska, E.Z.; Novikov, V.P. Synthesis, cytotoxicity by bioluminescence inhibition, antibacterial and antifungal activity of ([1,2,4]triazolo[1,5-c]quinazolin-2-ylthio)carboxylic acid amides. Arch. Pharm. Chem. Life Sci., 2009, 342, 651-662.
12. Tayal, G.; Srivastava, R.K.; and Arora, R.B. Anticonvulsant Activity of Some 2, 3-Disubstituted Fluoroquinazolones. Ind. J. Pharmac., 1975, 7, 84-87.
13. Mosaad, S.M.; Mohammed, K.I.; Ahmed, M.A.; Abdel-Hamide, S.G. New quinazoline related derivatives with antimicrobial activity: Part: II. J. Bio. Sci., 2004, 4, 504-509.
14. Smaill, J.B.; Palmer, B.D.; Rewcastle, G.W.; Denny, W.A.; McNamara, D.J.; Dobrusin, E.M.; Bridges, A.J.; Hairong Z.; Hollis Showalter, H.D.; Winters, R.T.; Leopold, W.R.; Fry, D.W.; Nelson, J.M.; Slintak, V.; Elliot, W.L.; Roberts, B.J.; Vincent, P.W.; Patmore, S.J. Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino) quinazoline and 4-(Phenylamino)pyrido[d]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor. J. Med. Chem., 1999, 42, 1803-1815.
15. Smaill, J.B.; Palmer, B.D.; Rewcastle, G.W.; Denny, W.A.; McNamara, D.J.; Dobrusin, E.M.; Bridges, A.J.; Hairong Z.; Hollis Showalter, H.D.; Winters, R.T.; Leopold, W.R.; Fry, D.W.; Nelson, J.M.; Slintak, V.; Elliot, W.L.; Roberts, B.J.; Vincent, P.W.; Patmore, S.J. Tyrosine Kinase Inhibitors. 18. 6-Substituted 4- Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor. J. Med. Chem., 2001, 44, 429-440.
16. Jantova, S.; Letasiova, S.; Repicky, A.; Ova dekova, R.; Lakatos, B. The effect of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4- yl[1,2,4]triazolo[4,3-c]quinazoline on cell growth, cell cycle, induction of DNA fragmentation, and activity of caspase 3 in murine leukemia L1210 cells and fibroblast NIH-3T3 cells. Cell Biochem. Funct., 2006, 24, 519-530.
17. Tsou, H.R.; Mamuya, N.; Johnson, B.D.; Reich, M.F.; Gruber, B.C.; Ye, F.; Nilakantan, R.; Shen, R.; Discafani, C.; DeBlanc, R.; Davis, R.; Koehn, F.E.; Greenberger, L.M.; Wang, Y.F.; Wissner, A. 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity. J. Med. Chem., 2001, 44, 2719-2734.
18. Khalil, A.A.; Abdel Hamide, S.G.; Al-Obaid, A.M.; El-Subbagh, H.I. Substituted Quinazolines, Part 2. Synthesis and In-Vitro Anticancer Evaluation of New 2-Substituted Mercapto-3Hquinazoline Analogs, Arch. Pharm. Pharm. Med. Chem., 2003, 2, 95-103.
19. Al-Obaid, A.M.; Abdel-Hamide, S.G.; El-Kashef, H.A.; Abdel- Aziz, A. M.; Al-Khamees, H.A.; El-Subbagh, H.I. Substituted Quinazolines, Part 3. Synthesis, In-Vitro Antitumor Activity and Molecular Modeling study of Certain 2-Thieno-4(3H)- quinazolinone Analogs. Arch. Pharm. Pharm. Med. Chem., 2003, 336, 95-125.
20. Chandrika, P.M.; Yakaiah, T.; Narsaiah, B.; Sridhar, V.; Venogopal, G.; Kumar, K.P. Synthesis leading to novel 2,4,6- trisubstituted quinazoline derivatives, their antibacterial and cytotoxic activity aginst THP-1, HL-60 and A-375 cell lines. Ind. J. Chem., 2009, 48, 840-847.
21. Pytel, D.; Sliwinski, T.; Poplawski, T.; Ferriola, D.; Majsterek, I. Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy. Anti-Cancer Agents in Med. Chem., 2009, 9, 66-76.
22. Kamath, S.; Buolamwini, J.K. Targeting EGFR and HER-2 ReceptorTyrosine Kinases for Cancer Drug Discovery and Development. Med. Research Reviews, 2006, 26, 569-594.
23. Abouzid, K.; Shouman, S. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. Bioorg. Med. Chem., 2008, 16, 7543-7551.
24. Denny, W.A.; Rewcastle, G.W.; Bridges, A.J.; Fry, D.W.; Kraker, A.J. Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. Clin. Exp. Pharmacol. Physiol., 1996, 23, 424-427.
25. Vasdev, N.; Dorff, P.N.; Gibbs, A. R.; Nandanan, E.; Reid, L.M.; O'Neil, J.P.; VanBrocklin, H.F. Synthesis of 6-acrylamido-4-(2- [18F]fluoroanilino)quinazoline: a prospective irreversible EGFR binding probe. J. Label Compd. Radiopharm., 2005, 48,109-115.
26. Smaill, J.B.; Palmer, B.D.; Rewcastle, G.W.; Denny, W.A.; McNamara, D.J.; Dobrusin, E.M.; Bridges, A.J.; Hairong Z.; Hollis Showalter, H.D.; Winters, R.T.; Leopold, W.R.; Fry, D.W.; Nelson, J.M.; Slintak, V.; Elliot, W.L.; Roberts, B.J.; Vincent, P.W.; Patmore, S.J. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino) quinazolineand 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem., 2000, 43, 1380-1397.
27. Klutchko, S.R.; Zhou, H.; Winters, R.T.; Tran, T.P.; Bridges, A.J.; Althaus, I.W.; Amato, D.M.; Elliott, W.L.; Ellis, P.A.; Meade, M.A.; Roberts, B.J.; Fry, D.W.; Gonzales, A.J.; Harvey, P.J.; Nelson, J.M.; Sherwood, V.; Han, H.K.; Pace, G. Smaill, J.B.; Denny, W.A.; and Hollis Showalter, H.D. Tyrosine Kinase Inhibitors. 19. 6-Alkynamides of 4-Anilinoquinazolines and 4- Anilinopyrido[3,4-d]pyrimidines as Irreversible Inhibitors of the erbB Family of Tyrosine Kinase Receptors. J. Med. Chem., 2006, 49, 1475-1485.
28. Noolvi M.N.; Patel, H.M. 3D QSAR studies on a series of quinazoline derrivatives as tyrosine kinase (EGFR) inhibitor: the knearest neighbor molecular field analysis approach. J. Basic and Clini. Pharm., 2010, 1, 153-175.
29. Oliveira, A.N.; Bocca, C.C.; Carvalho, J.E.; Ruiz, A.G.; Silva, T.P.; Rittner, R.; Hoehr, N.F. E. New substituted 4-arylaminoquinazolines as potent inhibitors of breast tumor cell lines: In vitro and docking experiments. J. Med. Chem., 2010, 45, 4339-4342.
30. Lee, J.; Nama, B.S.; Kim, H.; Oha, C.H.; Lee, S.H.; Cho, S.J.; Sim, T. B.; Hah, J.M.; Kim, D.J.; Tae, J.; Yoo, K.H. Synthesis of aminoquinazoline derivatives and their antiproliferative activities against melanoma cell line. Bioorg. Med. Chem. Lett., 2010, 20, 5722-5725.
31. Nam, B.S.; Kim, H.; Oh, C.H.; Lee, S.H.; Cho, S.J.; Sim, T.B.; Hah, J.M.; Kim, D.J.; Choi, J.H.; Yoo, K.H. Aminoquinoline derivatives with antiproliferative activity against melanoma cell line. Bioorg. Med. Chem. Lett., 2009, 19, 3517-3520.
32. Barche chath, S.; Williams, C.; Saade, K.; Lauwagie S.; Jean- Claude, B. Rational Design of Multitargeted Tyrosine Kinase Inhibitors: A Novel Approach. Chem. Biol. Drug Des., 2009, 73, 380-387.
33. Kawakami, J.K.; Martinez, Y.; Sasaki, B.; Harris, M.; Kurata, W.E.; Lau, A.F. Investigation of a novel molecular descriptor for the lead optimization of 4-aminoquinazolines as vascular endothelial growth factor receptor-2 inhibitors: Application for quantitative structure-activity relationship analysis in lead optimization. Bioorg. Med. Chem. Lett., 2011, 21, 1371-1375.
34. Ban, H.S.; Usui, T.; Nabeyama, W.; Morita, H.; Fukuzawa, K.; Nakamura, H. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase. Org. Biomol. Chem., 2009, 7, 4415-4427.
35. Liu, L.T.; Yuan, T.T.; Liu, H.H.; Chena, S.F.; Wu, Y.T. Synthesis and biological evaluation of substituted 6-alkynyl-4- anilinoquinazoline derivatives as potent EGFR inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 6373-6377.
36. Ban, H.S.; Usui, T.; Nabeyama, W.; Morita, H.; Fukuzawa, K.; Nakamura, H. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines. Bioorg. Med. Chem. Lett., 2010, 18, 870-879.
37. Bathini, Y.; Singh, I.; Harvey, P.J.; Keller, P.R.; Singh, R.; Micetich, R.G.; Fry, D.W.; Dobrusin, E.M.; Toogood, P.L. 2- Aminoquinazoline inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem. Lett., 2005, 15, 3881-3885.
38. Discafani, C.M.; Carroll, M.L.; Floyd, M. B.; Hollander, I.J.; Husain, Z.; Johnson, B.D.; Kitchen, D.; May, M.K.; Malo, M.S.; Minnick, A.A.; Nilakantan, R.; Shen, R.; Wang, Y.F.; Wissner A.; Greenberger, L.M. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3- bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochemical Pharmacology, 1999, 57, 917.
39. Myersa, M.R.; Setzera, N.N.; Spadaa, A.P.; Zullia, A.L.; Hsub, C.J.; Zilbersteinb, A.; Johnsonb, S.E.; Hookb L.E.; Jacoski, M.V. The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)- quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity. Bioorg. Med. Chem. Lett., 1997, 7, 417-420.
40. Fernandes, D.J.; Bertino J.R.; Hynes, J.B. Biochemical and Antitumor Effects of 5,8-Dideazaisopteroylglutamate, a Unique Quinazoline Inhibitor of Thymidylate Synthase. Cancer Res., 1983, 43, 1117-1123.
41. Lichtner, R.B.; Menrad, A.; Sommer, A. Signaling-inactive Epidermal Growth Factor Receptor/Ligand Complexes in Intact Carcinoma Cells by Quinazoline Tyrosine Kinase Inhibitors. Cancer Res., 2001, 61, 5790-5795.
42. Meng, X.Y.; Zhang, X.P.; Li, B.S.; Li, G.D. Synthesis and antimalarial and antineoplastic activities of some derivatives of 2,4- diamino-5-methyl-6-substituted benzylaminoquinazolines. Yao Xue Xue Bao, 1989, 24, 578-586.
43. Liu, J.Q.; Xu, X.G.; Chen, X.H.; Yu, A.Z.; Dai, Z.R.; Zhang, X.P. 60. Synthesis and biological activities of 2,4-diamino-5-chloro-6- substituted quinazolines. Yao Xue Xue Bao, 1991, 26, 821-828.
44. Gawad, N.M.; George, H.H.; Youssef R.M.; El-Sayed, N.A. Synthesis and antitumor activity of some 2, 3-disubstituted quinazolin-4(3H)-ones and 4, 6- disubstituted- 1, 2, 3, 4- tetrahydroquinazolin-2H-ones. E. J. Med. Chem., 2010, 45, 6058-6067.
45. Zhou, W.C.; Xin, Z.M.; Li, B.S.; Li, G.D.; Zhang, X.P. Synthesis and antimalarial as well as antitumor activities of 1-methyl-2,4- diamino-6-(N-methyl-substituted benzylamion) quinazolinium iodides. Yao Xue Xue Bao, 1989, 24, 953-956.
46. Zhou, W.C.; Li, G.Y.; Xin, Z.M.; Li, B.S.; Chen, G.D.; Dai, Z.R.; Zhang, X.P. Synthesis and antimalarial as well as antitumor activities of 2,4-diamino-6-(N-methyl-substituted benzylamino) quinazolines. Yao Xue Xue Bao, 1989, 24, 99-104.
47. Meng, X.Y.; Zhang, X.P.; Chen, X.H.; Yu, A.Z. Synthesis and antibacterial as well as antineoplastic activities of 2,4-diamino-5- methyl-6-(N-methyl-substituted benzyl) aminoquinazolines. Yao Xue Xue Bao, 1991, 26, 383-386.
48. Park, H.J.; Kim, Y.S.; Kim, J.S.; Lee, E.J.; Yi, Y.J.; Hwang, H.J.; Suh, M.E.; Ryu, C.K.; Lee, S.K. 6-Arylamino-7-chloro-quinazoline- 5,8-diones as novel cytotoxic and DNA topoisomerase inhibitory agents. Bioorg. Med. Chem. Lett., 2004, 14, 3385-3388.
49. Zhang, Y.; Chen, Z.; Lou, Y.; Yu, Y. 2,3-Disubstituted 8- arylamino-3H-imidazo[4,5-g]quinazolines A novel class of antitumor agents. E. J. Med. Chem., 2009, 44, 448-452.
50. Ye, Z.Q.; Ding, W.B.; Chen, Z.; Zhang, Y.D.; Yu, Y.P.; Lou, Y. 4, 8-disubstituted-8, 9-dihydro-pyrazine[2,3-g]quinazoline-7(6H)-ketones: a novel class of antitumor agents. Xue Xue Bao Yi Xue Ban, 2010, 39, 49-56.
51. Denny, W.A. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. Farmaco., 2001, 56, 51-56.
52. Tsou, H.R.; Mamuya, N.; Johnson, B.D.; Reich, M.F.; Gruber, B.C.; Ye, F.; Nilakantan, R.; Shen, R.; Discafani, C.; DeBlanc, R.; Davis, R.; Koehn, F.E.; Greenberger, L.M.; Wang, Y.F.; Wissner, A. 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity. J. Med. Chem., 2001, 44, 2719-2734.
53. Liu, Y.; Poon, R.T.; Shao, W.; Sun, X.; Chen, H.; Kok, T.W.; Fan, S.T. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. Cancer Lett., 2007, 248, 32-40.
54. Zhang, Y.; Chen, Z.; Lou, Y.; Yu, Y. 2,3-Disubstituted 8- arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents. E. J. Med. Chem., 2009, 44, 448-452.
55. Benning, C.M.; Kyprianou, N. Quinazoline-derived a1- Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis Via an α 1-Adrenoceptor-independent Action. Cancer Res., 2011, 62, 597-602.